18 stories mentioning BOM:532321Updated 16d ago
Every FINWIRES story that references BOM:532321, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said its Phase 2(b) clinical trial of Saroglitazar Magnesium in patients with MASH and liver fibrosis met its primary endpoint.The trial showed that the treatment helped resolve steatohepatitis without worsening fibrosis at 52 weeks. The study enrolled 189 patients and also showed improvements in liver fat, inflammation and other liver-related measures.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC, at GIFT City on Aug. 25, according to an Indian bourse filing on Wednesday.Shares of the company rose over 1% in recent trade.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received final U.S. Food and Drug Administration approval for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP in two strengths.The product is a generic equivalent of Ascor Injection and has been designated a Competitive Generic Therapy by the U.S. FDA, according to a Friday filing on Indian bourses. It is used for the short-term treatment of scurvy in patients aged 5 months and older who cannot take vitamin C orally.
Zydus Lifesciences' (NSE:ZYDUSLIFE, BOM:532321) U.S. unit Sentynl Therapeutics has entered into an agreement with Mereo BioPharma Group for rights to alvelestat, an experimental treatment for a rare genetic lung disease.Under the agreement, Sentynl will have an option to license U.S. commercial rights and will receive global manufacturing rights, according to an Indian bourse filing on Tuesday. If the option is exercised, Mereo will receive up to $40 million in upfront and research payments through regulatory filing, plus tiered royalties on U.S. sales.The drug is being prepared for Phase 3 trials, which could begin in early 2027.Zydus shares fell nearly 2% in recent trade.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) reported a 35.9% year-over-year drop in consolidated net profit in the fiscal first quarter, weighed down by ballooning expenses that offset the 22% jump in revenue.Net profit plunged to 9.40 billion rupees from 14.7 billion rupees a year earlier, with earnings per share also falling to 9.35 rupees from 14.58 rupees, the Indian drugmaker said in a bourse filing on Tuesday.Meanwhile, revenue from operations rose 22% to 80.2 billion rupees, the company's highest quarterly revenue on record, from 65.7 billion rupees a year ago.In a presentation on Tuesday, Zydus attributed the revenue growth to its core pharmaceutical business as India-branded formulations sustained robust growth momentum and outpaced the market growth for another quarter.The company said its North America formulations business expanded sequentially on the back of sustained volume expansion and new product launches.However, larger expenses hit the company's bottom line as total expenses ballooned to 25.4 billion rupees from 22.7 billion rupees.During the quarter, Zydus booked severance compensation of 1.09 billion rupees tied to its acquisition of Assertio Holdings. It also booked 559 million rupees as a provision to settle a class action lawsuit.Looking ahead, Zydus reaffirmed its fiscal 2027 outlook for strong double-digit revenue growth and an EBITDA margin of 24% or more.During an earnings call, Zydus CFO Tushar Shroff said the company expects 30 to 40 new US product launches in the current fiscal year.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration with a voluntary action indicated (VAI) classification for its injectable manufacturing facility at Zydus Biotech Park in Ahmedabad.The good manufacturing practices inspection was conducted from April 27 to May 5, according to a Saturday filing with the Indian bourses.A VAI classification means the USFDA identified objectionable conditions or practices but does not plan to take or recommend regulatory or administrative action, according to the USFDA website.Shares of the company fell nearly 1% in early trade on Monday.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has been ordered to pay an amount of 108.5 million Indian rupees in deficient stamp duty related to the acquisition of land, building, plant, and machinery assets from Sterling Biotech.The amount, comprising a deficient stamp duty of 53.5 million rupees and penalties of 55.1 million rupees, has been ordered by the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, according to a Wednesday Indian bourse filing.The order came after the authority determined the market value of the assets was higher than the value adopted for stamp duty purposes.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) restarted operations at its facilities in India's Ahmedabad region after temporarily suspending some activities due to torrential rain and waterlogging.Operations at the affected sites were halted as a precautionary measure and are being restored as weather conditions improve, according to an Indian bourse filing on Saturday.Shares of the company rose nearly 1% in Monday morning trade.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received approval to conduct a Phase III clinical trial of Desidustat in patients with sickle cell disease.The 203-day study, to be conducted in collaboration with the Indian Council of Medical Research, will evaluate the efficacy and safety of Desidustat oral tablets for treating anemia associated with the disease, according to an Indian bourse filing on Thursday.The trial is expected to enroll 164 patients.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has signed a memorandum of understanding (MoU) with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India.The MoU follows Zydus Lifesciences' exclusive arrangement with Guardant Health to introduce the blood-based cancer screening test in the country, according to a stock exchange filing on Friday.Shield MCD is a methylation-based blood test designed to screen for multiple cancers, including breast, lung, colorectal, and prostate cancers, using a single blood sample.Shares of the company rose over 3% in recent trade.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has entered into a share subscription and shareholders' agreement with Sunshine Healthcare Lanka and Zydus Sunshine Lifesciences to acquire a 50% stake in the latter.Post investment, Zydus Sunshine will operate as a 50:50 joint venture between Zydus and Sunshine Healthcare and will set up a pharmaceutical manufacturing facility in Sri Lanka's Horana Export Processing Zone, according to a stock exchange filing on Friday.The investment of up to $5 million will be completed within 90 working days of execution of the agreement.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), through its wholly-owned subsidiary, Zara Merger Sub, has completed the acquisition of all outstanding shares of common stock of NASDAQ-listed Assertio Holdings, according to a Tuesday filing to the Indian stock exchanges.The purchase was done at $23.50 per share of common stock of the U.S.-based specialty oncology pharmaceutical company Assertio, as part of a merger deal amounting to a total consideration of $166.3 million on a fully diluted basis.After the completion of the merger, Assertio will be the surviving entity, in which all shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $23.50 offer price per common share.Assertio will become a wholly-owned subsidiary of the company, and its common stock will no longer be listed or traded on the Nasdaq, the statement said.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said appellate authorities in Chhattisgarh, India, have substantially reduced tax demands and penalties imposed on its wholly owned subsidiary, Zydus Healthcare, in input tax credit (ITC) cases for financial years 2018-19 and 2019-20, according to a Tuesday filing on Indian bourses.For the financial year 2018-19, demand was reduced to 24,000 rupees from 2.9 million rupees, including penalty, the company said in the filing.For the financial year 2019-20, demand was cut to 20,000 rupees from around 1.3 million rupees, including penalty, it added.The relief was granted through orders passed by the Appellate Additional Commissioner of State, Chhattisgarh, the company said.Shares of Zydus Lifesciences rose 1% in recent trade.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said it received a warning letter from the U.S. Food and Drug Administration related to its formulations manufacturing facility in Baddi, Himachal Pradesh, according to a Wednesday filing on Indian bourses.The warning letter was issued in response to a records request under the Federal Food, Drug, and Cosmetic Act, the company said. It relates to observations regarding the use of purified talc that did not meet current U.S. Pharmacopeia requirements.Zydus said the letter is not linked to an on-site inspection and does not affect current operations or supplies from the facility.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has an average rating of overweight and mean price target of 1,031.39 Indian rupees, according to analysts polled by FactSet.
Indian benchmark indices ended sharply higher on Wednesday as reports of a possible U.S.-Iran deal supported global risk sentiment.The BSE Sensex rose 940.73 points, or 1.22%, to close at 77,958.52, while the NSE Nifty 50 gained 298.15 points, or 1.24%, to settle at 24,330.95.Markets advanced on expectations that the U.S. and Iran may be close to resolving their conflict, which had pushed energy prices higher in recent sessions. Hopes of easing geopolitical risks supported sentiment and helped drive broad-based buying.In economic news, Services activity in Indian strengthened in April, with the HSBC India Services PMI rising to 58.8 from 57.5, supported by firm domestic demand and e-commerce growth. New orders saw the fastest expansion in five months, aided by pricing strategies and demand for logistics and relocation services. However, export growth slowed to a five-month low amid Middle East tensions and weak tourism.In earnings news, Aditya Birla Real Estate (NSE:ABREL, BOM:500040) gained nearly 5% after reporting a profit of 108.4 million rupees in Q4, compared with a loss of 1.31 billion rupees a year earlier, according to a filing. Revenue from operations declined to 981.9 million rupees from 4.08 billion rupees.Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) rose over 3% after receiving seven observations from the US FDA following an inspection of its Ahmedabad facility, according to a Wednesday filing.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received seven observations from the US Food and Drug Administration (US FDA) following the inspection of its Unit 9 facility located at Zydus Biotech Park in Ahmedabad, India, according to a Wednesday filing to the India stock exchanges.The regulator inspected the Ahmedabad unit from April 27 to May 5.The company plans to closely work with the USFDA for work on resolving the observations expeditiously.The company's shares were up nearly 3% in recent trade.
Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received the establishment inspection report and approval letter from the US Food and Drug Administration for its oncology injectable manufacturing site in Ahmedabad, India.The US FDA conducted a pre-approval inspection at the facility in November 2025 in relation to the new isolator injectable line, according to a Thursday filing to the Indian stock exchanges.
